Key result
Pioglitazone preserves myocardial ATP during ischemia via a nitric oxide synthase-dependent mechanism.
Why the study?
The effects of pioglitazone and metformin on myocardial metabolism during ischemia and their association with nitric oxide are poorly understood.
Does pioglitazone or metformin improve myocardial energy metabolism during ischemia in isolated rabbit hearts, and is this effect mediated by nitric oxide?
Does pioglitazone or metformin improve myocardial energy metabolism during ischemia in isolated rabbit hearts, and is this effect mediated by nitric oxide?
Pioglitazone and metformin provide cardioprotection during ischemia in isolated rabbit hearts by improving myocardial energy metabolism, an effect that appears to be mediated by nitric oxide synthase.
Answers are grounded in this paper and cite their sources.
Pioglitazone and metformin preserve ATP via NO during rabbit ischemia; leaves open translation to human cardioprotection.
BACKGROUND: The effects of two drugs representing different classes of antidiabetic pharmacology (pioglitazone, a thiazolidinedione; and metformin, a biguanide) on the myocardial metabolism in the ischemia are poorly understood. METHODS: To test the hypothesis that cardioprotection of pioglitazone and metformin is associated with nitric oxide (NO), we studied the high energy phosphate metabolism by 31P-nuclear magnetic resonance (NMR) in isolated rabbit hearts. Forty-five minutes of continuous normothermic global ischemia was carried out. Pioglitazone or metformin was administered at the beginning, 60 min prior to the global ischemia, with or without the nitric oxide synthase inhibitor, L-NAME, administered 5 min or 60 min prior to the ischemia. In the first experiment, whether NO was produced or not by administration of pioglitazone, for the prevention of myocardial ischemic injury, was investigated. Hearts of male Japanese white rabbits were divided into 4 experimental groups: the control (C) group, the P group consisting of pioglitazone treatment, the P + L5 group consisting of pioglitazone treatment with L-NAME (5 min before ischemia), and the P + L60 group consisting of pioglitazone treatment with L-NAME (60 min before ischemia). In the next experiment, a comparison between the effects of pioglitazone and metformin in preventing ischemic injury were studied. The hearts were divided into 4 experimental groups: the control (C) group, the P group consisting of pioglitazone treatment, the P + L5 group consisting of pioglitazone treatment with L-NAME (5 min before ischemia), the M group consisting of metformin treatment, and the M + L5 group consisting of metformin treatment with L-NAME (5 min before ischemia). RESULTS: In the first experiment, the decrease in adenosine triphosphate (ATP) during ischemia was significantly inhibited in the P group in comparison with the C group (P < 0.01). However, the decrease in ATP was not inhibited in the P + L5 group during ischemia. In contrast, in the P + L60 group, the decrease in ATP was not inhibited during a part of ischemia. In the next experiment, a comparison between the effects of pioglitazone and metformin in preventing ischemic injury was studied. As a result of administration of either pioglitazone or metformin, there was no difference between groups with and without L-NAME. CONCLUSION: These results suggest that pioglitazone has a significant beneficial effect on improving the myocardial energy metabolism during ischemia. This cardioprotection may be dependent on nitric oxide (NO) synthase during ischemia more than preischemia. Furthermore, the present findings suggest that both pioglitazone and metformin have equal cardioprotective effects mediated by NO on myocardial ischemic injury in rabbits.
No takes yet. Share an insight, caveat, or question.
Kawabata et al. (2003) studied Myocardial ischemia. Pioglitazone and metformin vs. Control (no treatment) and L-NAME was evaluated on Decrease in adenosine triphosphate (ATP) during ischemia (p=< 0.01). Pioglitazone inhibited the decrease in ATP during myocardial ischemia compared to control, a cardioprotective effect that was abolished by nitric oxide synthase inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: